Background: The authors note that special literature does not make mention of drugs for targeted, specific correction of retinal ischemia. That is why the study of the possibilities of pharmacological correction of ischemic and reperfusion injuries of the retina in the experiment is urgent. The aim of the study: To increase the effectiveness of pharmacological correction of ischemic and reperfusion injuries of the retina by using types I, II agonists of imidazoline receptors. Materials and methods: Evaluation of the protective properties of imidazoline receptor agonists in a retinal ischemia-reperfusion model in Wistar rats by using C7070 substance (3- (1H-benzimidazol-2-yl) -1,2,2-trimethylcyclopentanecarboxylic acid) in doses of 10 mg/kg and 50 mg/kg and potassium salt of C7070 in a dose of 10 mg/kg were performed according to the dynamics of morphometric parameters of the thickness of retinal layers. Results: On the model of retinal ischemia-reperfusion, it was shown that the potassium salt of C7070 has a more pronounced retinoprotective effect than C7070. With correction by C7070 in a dose of 10 mg/kg, the photoreceptor layer is 10.9% (p>0.05) thicker compared with the value in the group with the pathology model and does not differ significantly from it; the inner nuclear layer is 21.6% thicker than in the group with the model (p<0.05); the thickness of the ganglionic layer and nerve fibers is not significantly different from the value in the group with the pathology model. With correction by C7070 in a dose of 50 mg/kg with potassium salt of C7070 in a dose of 10 mg/kg, the thickness of the photoreceptor layer, inner nuclear layer, ganglionic layer and nerve fibers does not differ significantly from the corresponding values of the norm. Conclusion: The experiment has revealed that the substance of potassium salt of C7070 in a dose of 10 mg/kg has a retinoprotective effect, which consists in preserving the structure of the nuclear layers of the retina and the layer of photoreceptors, and reducing the ischemic damage to the retina.
Background: The authors note that special literature does not make mention of drugs for targeted, specific correction of retinal ischemia. That is why the study of the possibilities of pharmacological correction of ischemic and reperfusion injuries of the retina in the experiment is urgent. The aim of the study: To increase the effectiveness of pharmacological correction of ischemic and reperfusion injuries of the retina by using types I, II agonists of imidazoline receptors. Materials and methods: Evaluation of the protective properties of imidazoline receptor agonists in a retinal ischemia-reperfusion model in Wistar rats by using C7070 substance (3- (1H-benzimidazol-2-yl) -1,2,2-trimethylcyclopentanecarboxylic acid) in doses of 10 mg/kg and 50 mg/kg and potassium salt of C7070 in a dose of 10 mg/kg were performed according to the dynamics of morphometric parameters of the thickness of retinal layers. Results: On the model of retinal ischemia-reperfusion, it was shown that the potassium salt of C7070 has a more pronounced retinoprotective effect than C7070. With correction by C7070 in a dose of 10 mg/kg, the photoreceptor layer is 10.9% (p>0.05) thicker compared with the value in the group with the pathology model and does not differ significantly from it; the inner nuclear layer is 21.6% thicker than in the group with the model (p<0.05); the thickness of the ganglionic layer and nerve fibers is not significantly different from the value in the group with the pathology model. With correction by C7070 in a dose of 50 mg/kg with potassium salt of C7070 in a dose of 10 mg/kg, the thickness of the photoreceptor layer, inner nuclear layer, ganglionic layer and nerve fibers does not differ significantly from the corresponding values of the norm. Conclusion: The experiment has revealed that the substance of potassium salt of C7070 in a dose of 10 mg/kg has a retinoprotective effect, which consists in preserving the structure of the nuclear layers of the retina and the layer of photoreceptors, and reducing the ischemic damage to the retina.